Boccalini Sara, Bechini Angela, Alimenti Cecilia Maria, Bonanni Paolo, Galli Luisa, Chiappini Elena
Department of Health Sciences, University of Florence, Viale GB Morgagni, 48 - 50134 Florence, Italy.
Meyer Children's University Hospital, Viale Pieraccini 24 - 50139 Florence, Italy.
Vaccines (Basel). 2020 Feb 1;8(1):60. doi: 10.3390/vaccines8010060.
The appropriate immunization of internationally adopted children (IAC) is currently under debate and different approaches have been suggested. The aim of this study is to evaluate the clinical and economic impact of different strategies of measles, mumps, rubella, and varicella (MMRV) immunization in IAC in Italy. A decision analysis model was developed to compare three strategies: presumptive immunization, pre-vaccination serotesting and vaccination based on documentation of previous immunization. Main outcomes were the cost of strategy, number of protected IAC, and cost per child protected against MMRV. Moreover, the incremental cost-effectiveness ratio (ICER) was calculated. The strategy currently recommended in Italy (immunize based on documentation) is less expensive. On the other hand, the pre-vaccination serotesting strategy against MMRV together, improves outcomes with a minimum cost increase, compared with the presumptive immunization strategy and compared with the comparator strategy. From a cost-effectiveness point of view, vaccination based on serotesting results in being the most advantageous strategy compared to presumptive vaccination. By applying a chemiluminescent immunoassay test, the serology strategy resulted to be clinically and economically advantageous. Similar results were obtained excluding children aged <1 year for both serology methods. In conclusion, based on our analyses, considering MMRV vaccine, serotesting strategy appears to be the preferred option in IAC.
国际收养儿童(IAC)的适当免疫接种目前仍在讨论中,并且已经提出了不同的方法。本研究的目的是评估意大利IAC中麻疹、腮腺炎、风疹和水痘(MMRV)不同免疫策略的临床和经济影响。开发了一个决策分析模型,以比较三种策略:推定免疫、接种前血清检测以及根据既往免疫记录进行接种。主要结果包括策略成本、获得保护的IAC数量以及每名获得MMRV保护的儿童的成本。此外,还计算了增量成本效益比(ICER)。意大利目前推荐的策略(根据记录进行免疫接种)成本较低。另一方面,与推定免疫策略以及对照策略相比,针对MMRV的接种前血清检测策略能以最小的成本增加改善结果。从成本效益的角度来看,与推定接种相比,基于血清检测的接种是最具优势的策略。通过应用化学发光免疫分析测试,血清学策略在临床和经济方面都具有优势。在两种血清学方法中排除<1岁儿童后也获得了类似结果。总之,根据我们的分析,考虑到MMRV疫苗,血清检测策略似乎是IAC中的首选方案。